SGCM
BPMC

Sand Grove Capital Management’s Blueprint Medicines BPMC Stock Holding History

Sand Grove Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-211,124
Closed -$27.1M – 15
2025
Q2 		$27.1M Buy
+211,124
New +$21.9M 13.62% 2

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sand Grove Capital Management's BPMC Position: Q3 2025 in Review

Sand Grove Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 211,124 shares — an estimated $27.1M sold.

Sand Grove Capital Management first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $27.1M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Sand Grove Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Sand Grove Capital Management sold 211,124 Blueprint Medicines shares in Q3 2025, an estimated $27.1M.
  • Sand Grove Capital Management first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Sand Grove Capital Management's Blueprint Medicines position peaked at $27.1M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Sand Grove Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.